Anagrelide (hydrochloride)

Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM) . Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action[1][2][3].

Product Specifications

CAS Number

[58579-51-4]

Product Name Alternative

BL4162A

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Anagrelide-hydrochloride.html

Purity

99.39

Solubility

DMSO : 6.36 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

ClC1=C(CN(C2)C3=NC2=O)C(N3)=CC=C1Cl.Cl

Molecular Formula

C10H8Cl3N3O

Molecular Weight

292.55

Precautions

H302, H315, H319, H335

References & Citations

[1]Pescatore, S.L. and C. Lindley, Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother, 2000. 1 (3) : p. 537-46.|[2]Petrides, P.E., Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost, 2006. 32 (4 Pt 2) : p. 399-408.